AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04587505 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural anesthesia with light general anesthesia
Description: Epidural anaesthesia: mixture of ropivacaine 6.5 mg/ ml and fentanyl 8.3 μg/ml. Light general anesthesia: isoflurane in mixture of 50/50 of nitrous oxide and oxygen to achieve Minimum alveolar concentration between 0.6 and 0.8.
Study NCT04587505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative epidural analgesia
Description: Before the end of operation was given 4 ml of the mixture of ropivacaine 4.4 mg/ml and morphine 0.8mg/ ml. Epidural analgesia was continued for next 24 hours with a mixture of ropivacaine 2.2 mg/ml and morphine 0.4 mg/ml.
Study NCT04587505 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: Maintaining general anesthesia: nitrous oxide and oxygen in mixture 50/50 and isoflurane to achieve minimum alveolar concentration between 0.8 and 1. Fentanyl loading dose: 6-8 μg/kg. Additional fentanyl doses were given incrementally.
Study NCT04587505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuous intravenous analgesia
Description: Tramadol 100 mg in the first hour followed by tramadol 300 mg continuously for the next 24 hours.
Study NCT01057459 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03978728 — intervention group
Intervention type: DEVICE
Intervention: Extra-corporeal membrane oxygenation
Description: Cardiovascular shock patients received extra-corporeal membrane oxygenation suppot.
Study NCT00537212 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The South Beach Diet
Description: Subjects will receive dietary counselling aimed at reducing simple carbohydrates and increasing weight loss. Subjects also receive a copy of The South Beach Diet.
Study NCT00537212 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The Ornish Diet
Description: Subjects will receive dietary counselling aimed to reduce fat consumption and increase weight loss. Subjects also receive a copy of The Ornish Diet book.
Study NCT00537212 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control Group
Description: This group will receive phototherapy alone. They will not be counselled or give literature on a particular diet.
Study NCT05122468 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Connective tissue Harvest and CAF
Description: A connective tissue graft will be harvested from the palate as a free gingival graft, which will be de-epithelialized with a 15-c blade(Zucchelli et al. 2010) before opening of the opaque envelopes, which contains the allocation concealment. The dimensions of the graft achieve 3 to 5 mm mesial and distal from the lateral teeth with an ideal thickness about 1 to 1.5 mm. Donor tissue will be taken at premolar and molar level. In control sites, the graft will be adapted to cover each exposed root to the CEJ, and stabilized with either 6-0 resorbable sutures (with the knot placed under the papillary area) or a non-resorbable suture with the knot on the palatal side. For suturing of the graft, interrupted sutures or sling sutures (anchored to periosteum apical to the graft and hanging around the neck of the experimental teeth) may be used.
Study NCT04922775 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Chinese medicine technique taping
Description: Participants will accept Chinese medicine technique taping before muscle fatigue exercise.
Study NCT05122468 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Connective tissue Harvest and Tunnel
Description: A connective tissue graft will be harvested from the palate as a free gingival graft, which will be de-epithelialized with a 15-c blade(Zucchelli et al. 2010) before opening of the opaque envelopes, which contains the allocation concealment. The dimensions of the graft achieve 3 to 5 mm mesial and distal from the lateral teeth with an ideal thickness about 1 to 1.5 mm. Donor tissue will be taken at premolar and molar level.~In test sites, the graft should be slid through the tunnel. To accomplish the adequate position of the graft into the tunnel, 2 sutures are first placed, 1 at the most mesial and the other at the most distal aspect of the tunnel. The needles should pass underneath the tunnel and exit through the largest or most central gingival recession, the one through which the grafting tissue will be introduced. With these 2 sutures already inside the tunnel, the graft is bitten on both ends with vertical mattress sutures.
Study NCT03856619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TERIFLUNOMIDE HMR1726
Description: Pharmaceutical form: Tablet~Route of administration: Oral
Study NCT00478595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimonabant
Description: Tablet, oral administration
Study NCT00478595 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Rimonabant)
Description: Tablet, oral administration
Study NCT00478595 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anti-diabetic monotherapy
Description: Previous treatment with Sulfonylurea or α-glucosidase inhibitor continued at stable dose during the study period
Study NCT00478595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-diabetic monotherapy
Description: Previous treatment with Sulfonylurea or α-glucosidase inhibitor continued at stable dose during the study period
Study NCT02543606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomelone
Description: powder for injection/ infusion Esomeprazole 40mg
Study NCT02543606 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomelone
Description: powder for injection/ infusion Esomeprazole 40mg
Study NCT02543606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexium
Description: powder for injection/ infusion Esomeprazole 40mg
Study NCT02543606 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nexium
Description: powder for injection/ infusion Esomeprazole 40mg
Study NCT04252391 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Perineural electrical dry needling
Description: Standard care plus use of perineural electrical dry needling involving use of a monofilament needle of 15 or 30 mm length, 0.25 mm diameter will be placed utilizing the therapist's dominant hand following palpation of correct needle location. An electrical stimulation unit will be used to conduct an electrical impulse. The unit used will be an ES-130 by ITO (Japan) using a DC 9V battery producing an asymmetrical biphasic waveform. The unit has 6 available leads with alligator clamps, connecting to needle shafts. Parameters of PNED will include intensity set at a strong yet comfortable setting according to patient feedback. Treatment duration will be 15 minutes. Treatment frequency will be set to Medium at level 8 (80 Hz). Parameters will be set to elicit a sensory response.
Study NCT04252391 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: cervical or thoracic manipulation or mobilization, muscle stretching, muscle strengthening, electrical trigger point dry needling , soft tissue release and prescribed therapeutic exercises .
Study NCT03001791 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Excisional biopsy with Er:YAG laser
Description: Excisional biopsy of fibrous hyperplasia in the buccal mucosa in local anesthesia with Er:YAG laser (Lite TouchTM, Synergon Dental Lasers, Light instruments Ltd., Yokneam Elite, Israel), λ = 2940nnm. Soft tissue biopsy mode with water cooling, frequency 35 Hz, pulse duration 250-390 µsec, pulse energy of 200 mJ, power 7 Watt . Cylindrical sapphire tip, 400 µm in diameter, without contact to the tissue.
Study NCT03001791 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Excisional biopsy with CO2 laser
Description: Excisional biopsy of fibrous hyperplasia in the buccal mucosa in local anesthesia with CO2 laser (Spectra DENTA Surgical Carbon Dioxide Laser, MAX Engineering Ltd., Gyeonggi-Do, Korea), λ = 10'600nnm. cf mode (frequency 140 Hz, pulse duration 400 µsec, pulse energy 33 mJ,a power 4.62 watts). Laser beam with a spot size of 0.2 mm, non-contact mode.
Study NCT03001791 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Excisional biopsy with scalpel
Description: Excisional biopsy of fibrous hyperplasia in the buccal mucosa in local anesthesia with scalpel (blade 15C). Polyamide sutures (Seralon 5-DS15, Serag Wiessner KG, Naila, Germany).
Study NCT01609491 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: phenylephrine
Description: If the mean arterial pressure drops below 20% of the baseline value and/or below 90 mmHg, a syringe pump with phenylephrine or norepinephrine (depending on randomisation) will be started. The anaesthetist will be blinded for the type of vasopressor. Concentrations phenylephrine (20 µg /ml) of Norepinephrine (10 µg/ml) will be used in the syringes
Study NCT01609491 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: norepinephrine
Description: If the mean arterial pressure drops below 20% of the baseline value and/or below 90 mmHg, a syringe pump with norepinephrine (depending on randomisation) will be started. The anaesthetist will be blinded for the type of vasopressor. Concentrations Norepinephrine (10 µg/ml) will be used in the syringes
Study NCT04594889 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: angioplasty
Description: Balloon releasing a drug inflated in the target vessel
Study NCT04594889 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: angioplasty
Description: Balloon releasing a drug inflated in the target vessel
Study NCT00420212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG00012
Study NCT00420212 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03998995 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immersive Virtual Reality
Description: An Oculus Rift VR Headset and a set of Oculus Touch Controllers was used as interactivity device. Two scenarios of IVR rehabilitation game were offered to the patients: 1) Archery based on behind-the-neck overhead press, using a quiver on the user back to encourage bending their arm and firing the arrow to help with stretching exercises and 2) Climbing based on an overhead arm raise exercise.~Each child will took part in a single IVR trial during their rehabilitation care with the physiotherapist, supported by IP, the games expert/researcher. Timing of participation was approximately 15 minutes of trial with each scenario of game. A short interview was conducted with each child and their parent (together) after each trial, and a focus group was conducted with the clinical staff.
Study NCT03363789 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Brisement injection
Description: An injection of Lidocaine into the tendon sheath to break up adhesions that could be causing the condition.
Study NCT03363789 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Patients will receive a prescription for physical therapy.
Study NCT01118585 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: TIF Procedure
Description: The TIF procedure results in the creation of an esophago-gastric fundoplication extending up to 4 cm above the Z-line and 270 degrees around the esophagus.
Study NCT00944476 — intervention group
Intervention type: PROCEDURE
Intervention: Fat-free MRI images utilizing standard magnetization, Questionnaire before the MRI exam
Description: In addition to the traditional MRI exam for clinical use, a fat-free MRI based on standard magnetization transfer magnetic resonance imaging will be acquired. Pts will spend 20 extra minutes and 20 minutes total for volunteers in the MRI scanner. Patients/volunteers will complete the MR Screening Questionnaire before the MRI exam.
Study NCT02647203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Self-administered fluoridated dentifrices
Description: Elderly participants will be instructed to self administer toothpastes, twice per day. Toothpastes will be provided.
Study NCT03837301 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NESS-EFTR with sentinel lymph node navigation
Description: Non-exposure Simple Suturing Endoscopic Full-Thickness Resection with sentinel lymph node navigation (basin dissection) for early gastric cancer patients
Study NCT00611416 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: green tea
Description: different catechin combinations
Study NCT00611416 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mix of catechins and caffeine
Description: 3 tablet a day
Study NCT00611416 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EGCG
Description: 3 tablets a day
Study NCT00611416 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EGC
Description: 3 tablets a day
Study NCT00611416 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Description: 3 tablets a day
Study NCT00611416 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 tablets a day
Study NCT03517735 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EasyTiva (algorithm is the property of Medsteer SAS)
Description: Propofol and Remifentanil are administered automatically using a closed-loop system. Bispectral index is used as the input signal and an algorithm defines the appropriate concentrations of propofol and remifentanil. Adequate postoperative sedation is defined by a bispectral index between 55 and 75.
Study NCT03517735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: The dosage is modified automatically by the device or according to the new medical prescription.
Study NCT03517735 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: The dosage is modified automatically by the device or according to the new medical prescription.
Study NCT03517735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: The dosage is modified automatically by the device or according to the new medical prescription.
Study NCT03517735 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: The dosage is modified automatically by the device or according to the new medical prescription.
Study NCT01149044 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Coronary Intervention with or without manual aspiration thrombectomy
Study NCT03793894 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation Counseling
Description: All participants will receive inpatient smoking cessation counseling by the tobacco-trained NP. Inpatient smoking cessation counseling is the standard of care at BMC.
Study NCT03793894 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Counseling
Description: All participants will receive inpatient smoking cessation counseling by the tobacco-trained NP. Inpatient smoking cessation counseling is the standard of care at BMC.
Study NCT03793894 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Decision Aid
Description: The AHRQ Is Lung Cancer Screening Right for me? patient decision aid is a 4-page paper format with the following features: 1) LDCT screening harms and benefits information, written in plain language and using pictographs, easily understood by those with low health literacy; 2) prompts to clarify patient values and preferences and to stimulate discussion about tradeoffs; 3) clear quit smoking messaging and resources (1-800-QUIT-NOW)
Study NCT03793894 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Aid
Description: The AHRQ Is Lung Cancer Screening Right for me? patient decision aid is a 4-page paper format with the following features: 1) LDCT screening harms and benefits information, written in plain language and using pictographs, easily understood by those with low health literacy; 2) prompts to clarify patient values and preferences and to stimulate discussion about tradeoffs; 3) clear quit smoking messaging and resources (1-800-QUIT-NOW)
Study NCT03793894 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shared decision making (SDM)
Description: During the smoking cessation consultation, the nurse practitioner (NP) will conduct SDM, using the 4-page AHRQ Is Lung Cancer Screening Right for me? decision aid as a guide. The purpose of SDM is three-fold: 1) conduct a tailored discussion on tradeoffs of LDCT screening, consistent with Centers for Medicare \& Medicaid Services (CMS) requirements for SDM using a decision aid; 2) directly connect interested patients to LDCT screening; 3) to empower and motivate patients to quit smoking within the LDCT screening context.
Study NCT03793894 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHW Navigation
Description: The CHW will meet with the participant after the SDM to initiate the coordination of outpatient tobacco treatment, referral to LCS, and resources to address the barriers to preventive services. The CHW will follow patients subjects in the intervention arm for 3 months to help navigate and address negative social determinants of health that are barriers to LCS and tobacco treatment. For patients who agree to screening, the CHW will schedule the appointment, arrange the transportation to appointment, and meet participant at the appointment to facilitate the screening.
Study NCT01392014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dihydroartemisinin-piperaquine
Description: This study used fixed-dose tablets of 40 mg dihydroartemisinin and 320 mg piperaquine for each tablet (D-ARTEPP®, Guilin Pharmaceutical Co., Ltd, China. The regimen is based on weight for 3 days (D0, D1 and D2) with maximal dose of 1 x 3 tablets for patients weighing ≥ 41 kg; 1 x 2 tablets for patients weighing 31 - 40 kg, 1 x 1.5 tablets for patients weighing 18 - 30 kg, and 1 X 1 tablet for patients with body weight of 11 - 17 kg.
Study NCT01392014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dihydroartemisinin-piperaquine + primaquine
Description: For DHP, treatment was as for Arm dihydroartemisinin piperaquine. A single dose PQ of 0.75 mg/kg BW was provided on Day-3 using 15 mg base PQ tablets (local product by PT Pharos Indonesia, batch no 15306002, produced on 30/05/2008 and expiring on May 2012). The maximal dose was 3 tablets for subjects weighing ≥ 60 kg. The dose range for subjects weighing 10 - 13 kg was 0.5 tablet; 14 - 18 kg was 0.75 tablet; 19 - 23 kg was 1 tablet, 24 -30 kg was 1.5 tablet; 31 - 40 kg was 2 tablets; 41- 49 kg was 2.25 tablet; 50 - 59 kg was 2.5 tablet and ≥ 60 kg was 3 tablets.
Study NCT03357328 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapy light room
Description: See group description
Study NCT02686398 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluad
Study NCT02686398 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Agrippal
Study NCT00837772 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard cutting guide for TKA
Description: Use of the usual cutting guide for surgical replacement of a diseased knee
Study NCT04463654 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zero Self-Harm app
Description: Safety plan app for smartphones
Study NCT00837772 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Otismed MRI generated cutting guide for TKA
Description: Use of the customized MRI generated cutting guide for surgical replacement of a diseased knee
Study NCT03781284 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18F]-FDG PET/MRI
Study NCT03781284 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Study NCT00265395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination of pegylated interferon alfa-2b (PEG-Intron®) and ribavirin (Rebetol®)
Description: 1. Powder for injection in vial or Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for 48 weeks~2. 200 mg capsules, oral, weight based dose of 800-1400 mg, daily for 48 weeks
Study NCT00265395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of pegylated interferon alfa-2b and ribavirin
Description: 1. Powder for injection in vial or Redipen (50, 80, 100, 120, and 150 microgram strength), subcutaneous, dose of 1.5 micrograms/kg, weekly for 72 weeks.~2. 200 mg capsules, oral, weight based dose of 800-1400 mg, daily for 72 weeks
Study NCT03168750 — intervention group
Intervention type: DEVICE
Intervention: Femoral Component:Medacta Masterloc Stem and Medacta MPACT cup.
Description: Total hip arthroplasty (THA) is one of the most commonly performed and successful orthopaedic operations in improving a patient's quality of life. Orthopaedic surgeons are continually striving to improve all aspects of care relating to this procedure whether this is improvements in implant technology, instrument improvement, or the technique involved in performing the procedure.The results of this study will establish the performance of the femoral component and acetabular component, and provide a general estimate of survivorship, clinical effectiveness and complications.
Study NCT03822988 — intervention group
Intervention type: OTHER
Intervention: no intervention, only complete a survey
Description: we will ask patients to answer to a survey
Study NCT03106922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMF104
Description: Powder for oral solution:~* Sachet A: macrogol 4000 52.500 g, anhydrous sodium sulphate 3.750 g, simeticone 0.080 g;~* Sachet B: sodium citrate 1.863 g, anhydrous citric acid 0.813 g, sodium chloride 0.730 g, potassium chloride 0.370 g;~One sachet A + 1 sachet B in 500 ml of water